Oncology

Underserved populations with limited access to medical care continue to be disproportionately impacted by certain cancers.

Olaparib was the first PARP inhibitor to be developed and has been the most studied.

The team found that out of more than 18,751 live births, 1008 cancer diagnoses were made in offspring 0 to 58 years of age.

Although specialty therapies have the potential to help people live healthier lives, their cost and complexity can create distinct challenges.

Ray Tancredi, RPh, MBA, divisional VP of specialty pharmacy development and brand Rx/vaccine purchasing at Walgreens, provides an analysis and overview of key specialty pharmaceuticals in development.

Survey results may imply that individuals who stop could have more health problems or die from a subsequent heart issue.

According to the researchers, almost half of the caregivers surveyed responded that the people they are caring for rely on them more than ever before, with 94% of respondents indicating that they put the needs of the person they care for above their own during the COVID-19 pandemic.

Besermi is an interferon alfa-2b indicated for the treatment of adults with polycythemia vera.

Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild type (WT) EGFR.

Patients with advanced renal cell carcinoma who were given the combination of nivolumab and ipilimumab demonstrated a significantly longer overall survival than those who received sunitinib.

Rituximab-pvvr is indicated for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis.

Investigators have developed an immunotherapy that is a potential option for children with hard-to-treat brain cancer.

The study’s identification of a network of possible candidate genes to carefully control for mutations could alter the future clinical implementation of CRISPR.

A survey of caregivers and parents of children with cancer shows that nearly one-third expressed hesitancy to vaccinate their youngsters against COVID-19.

Breast cancer found to be the most expensive type of the disease, costing approximately $3.4 billion in the United States.

Social determinants of health can play a significant role in the treatment trajectory and outcomes for patients with cancer because oncology care requires close communication between the patient and clinicians.

Study finds COVID-19 booster shot was extremely beneficial for all patients with cancer, especially those with a blood cancer.

Approximately 40% of patients with stage IV melanoma have brain metastases at diagnosis.

The results of a study showed that non-Hispanic Black patients treated with immunotherapy had a 15% lower risk of death from non–small cell lung cancer than non-Hispanic white patients.

Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Hodgkin lymphoma is most common in people between 20 and 40 years of age and those over 55 years of age.

Results of studies show about 61% of individuals with PV experienced a complete hematological response.

Pembrolizumab demonstrated a statistically significant improvement in disease-free survival, reducing the risk of disease recurrence or death by 32% compared to placebo.

Clinical trial findings show that the 2-year overall survival rate for those who received this was 72%.

Treatment for endometrial cancer includes surgery, radiation therapy, chemotherapy, immunotherapy, and supportive care.

Pharmacists should keep an eye on the pipeline for autologous and allogeneic CAR T-cell therapies as well as antibody-specific treatments.

Atrial fibrillation was more common in those not treated with radiation (66.5%) or surgery (23.5%) as first-line treatment compared with 52.3% and 10.4%, respectively.

The panel also recommends considering risk factors for poor response, including uncontrolled disease, immunoparesis, the number of previous lines of therapy, and patient age.